Drugs / ultralente
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00276393 | Jul 2002 → Dec 2003 | type 1 diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01798706 Background | Jun 2013 → Feb 2015 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ultralente | “We conducted a randomized crossover design clinical trial to compare glargine with ultralente insulin as a basal insulin in type 1 diabetes.” PMID 15616226 ↗ Jan 20051“Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗ |
| Known as | ultralente insulin | “To determine whether the use of glargine insulin as a basal insulin would result in a comparable HbA1c and less glycemic variation and hypoglycemia than ultralente insulin, 22...” PMID 15616226 ↗ Jan 2005 |